ACADIA Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 

CEO
Catherine Owen Adams
CEOCatherine Owen Adams
Employees
798
Employees798
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1993
Founded1993
Employees
798
Employees798

ACAD Key Statistics

Market cap
5.20B
Market cap5.20B
Price-Earnings ratio
13.59
Price-Earnings ratio13.59
Dividend yield
Dividend yield
Average volume
2.06M
Average volume2.06M
High today
$30.96
High today$30.96
Low today
$29.77
Low today$29.77
Open price
$30.73
Open price$30.73
Volume
1.15M
Volume1.15M
52 Week high
$30.96
52 Week high$30.96
52 Week low
$19.69
52 Week low$19.69

Stock Snapshot

As of today, ACADIA Pharmaceuticals(ACAD) shares are valued at $30.17. The company's market cap stands at 5.2B, with a P/E ratio of 13.59.

On 2026-08-19, ACADIA Pharmaceuticals(ACAD) stock moved within a range of $29.77 to $30.96. With shares now at $30.17, the stock is trading +1.3% above its intraday low and -2.6% below the session's peak.

Trading volume for ACADIA Pharmaceuticals(ACAD) stock has reached 1.15M, versus its average volume of 2.06M.

The stock's 52-week range extends from a low of $19.69 to a high of $30.96.

The stock's 52-week range extends from a low of $19.69 to a high of $30.96.

ACAD News

Simply Wall St 1d
Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD

In August 2026, ACADIA Pharmaceuticals Inc. reported past second-quarter 2026 results showing revenue of US$307.96 million and net income of US$31.5 million, wi...

Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD
TipRanks 2d
Acadia Pharmaceuticals price target raised to $49 from $45 at UBS

UBS raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $49 from $45 and keeps a Buy rating on the shares. Acadia is viewed favorably ahead of re...

Analyst ratings

76%

of 21 ratings
Buy
76.2%
Hold
19%
Sell
4.8%

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.